These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 30008461

  • 1. Zoster after Cyclophosphamide for Systemic Lupus Erythematosus or Vasculitis: Incidence, Risk Factors, and Effect of Antiviral Prophylaxis.
    Garnier C, Ribes D, Chauveau D, Huart A, Pugnet G, Adoue D, Prevot G, Alric L, Delobel P, Derumeaux H, Mengelle C, Sailler L, Moulis G.
    J Rheumatol; 2018 Nov; 45(11):1541-1548. PubMed ID: 30008461
    [Abstract] [Full Text] [Related]

  • 2. Risk factors for herpes zoster infection among Filipinos with systemic lupus erythematosus.
    Zamora LD, Collante MTM, Navarra SV.
    Int J Rheum Dis; 2020 Feb; 23(2):197-202. PubMed ID: 31692250
    [Abstract] [Full Text] [Related]

  • 3. Herpes zoster infection in childhood-onset systemic lupus erythematosus patients: a large multicenter study.
    Ferreira JC, Marques HH, Ferriani MP, Gormezano NW, Terreri MT, Pereira RM, Magalhães CS, Campos LM, Bugni V, Okuda EM, Marini R, Pileggi GS, Barbosa CM, Bonfá E, Silva CA.
    Lupus; 2016 Jun; 25(7):754-9. PubMed ID: 26821966
    [Abstract] [Full Text] [Related]

  • 4. Lupus mesenteric vasculitis: clinical features and associated factors for the recurrence and prognosis of disease.
    Yuan S, Ye Y, Chen D, Qiu Q, Zhan Z, Lian F, Li H, Liang L, Xu H, Yang X.
    Semin Arthritis Rheum; 2014 Jun; 43(6):759-66. PubMed ID: 24332116
    [Abstract] [Full Text] [Related]

  • 5. Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study.
    Hu SC, Yen FL, Wang TN, Lin YC, Lin CL, Chen GS.
    J Am Acad Dermatol; 2016 Jul; 75(1):49-58. PubMed ID: 26946984
    [Abstract] [Full Text] [Related]

  • 6. Lymphopaenia, anti-Ro/anti-RNP autoantibodies, renal involvement and cyclophosphamide use correlate with increased risk of herpes zoster in patients with systemic lupus erythematosus.
    Hu SC, Lin CL, Lu YW, Chen GS, Yu HS, Wu CS, Lan CC.
    Acta Derm Venereol; 2013 May; 93(3):314-8. PubMed ID: 22983107
    [Abstract] [Full Text] [Related]

  • 7. Herpes zoster in systemic lupus erythematosus.
    Manzi S, Kuller LH, Kutzer J, Pazin GJ, Sinacore J, Medsger TA, Ramsey-Goldman R.
    J Rheumatol; 1995 Jul; 22(7):1254-8. PubMed ID: 7562754
    [Abstract] [Full Text] [Related]

  • 8. Incidence, risk factors, and outcome of Herpes zoster in systemic lupus erythematosus.
    Borba EF, Ribeiro AC, Martin P, Costa LP, Guedes LK, Bonfá E.
    J Clin Rheumatol; 2010 Apr; 16(3):119-22. PubMed ID: 20216330
    [Abstract] [Full Text] [Related]

  • 9. Prevalence and risk factors of herpes zoster infection in patients with biopsy proven lupus nephritis undergoing immunosuppressive therapies.
    Mok CC, Tse SM, Chan KL, Ho LY.
    Lupus; 2020 Jul; 29(8):836-844. PubMed ID: 32408851
    [Abstract] [Full Text] [Related]

  • 10. Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications.
    Feldman CH, Marty FM, Winkelmayer WC, Guan H, Franklin JM, Solomon DH, Costenbader KH, Kim SC.
    Arthritis Rheumatol; 2017 Feb; 69(2):387-397. PubMed ID: 27589220
    [Abstract] [Full Text] [Related]

  • 11. Ovarian Insufficiency is Major Short-term Toxicity in Systemic Lupus Erythematosus Patients Treated with Cyclophosphamide.
    Singh G, Misra R, Aggarwal A.
    J Assoc Physicians India; 2016 Feb; 64(2):28-31. PubMed ID: 27730777
    [Abstract] [Full Text] [Related]

  • 12. [A multicenter study on the tolerance of intravenous low-dose cyclophosphamide in systemic lupus erythematosus].
    Shao M, Guo HF, Lei LY, Zhao Q, Ding YJ, Lin J, Wu R, Yu F, Li YC, Miao HL, Zhang LY, DU Y, Jiao RY, Pang LX, Long L, Li ZG, Li R.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Dec 18; 54(6):1112-1116. PubMed ID: 36533341
    [Abstract] [Full Text] [Related]

  • 13. The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease.
    Harward LE, Mitchell K, Pieper C, Copland S, Criscione-Schreiber LG, Clowse ME.
    Lupus; 2013 Jan 18; 22(1):81-6. PubMed ID: 23263867
    [Abstract] [Full Text] [Related]

  • 14. Assessment of ovarian reserve by serum anti-Müllerian hormone in patients with systemic lupus erythematosus: a meta-analysis.
    Luo W, Mao P, Zhang L, Chen X, Yang Z.
    Ann Palliat Med; 2020 Mar 18; 9(2):207-215. PubMed ID: 32156138
    [Abstract] [Full Text] [Related]

  • 15. Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus.
    Vlachoyiannopoulos PG, Toya SP, Katsifis G, Zintzaras E, Tzioufas AG, Moutsopoulos HM.
    J Rheumatol; 2008 Sep 18; 35(9):1768-75. PubMed ID: 18634157
    [Abstract] [Full Text] [Related]

  • 16. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
    Mok CC, Lau CS, Wong RW.
    Arthritis Rheum; 1998 May 18; 41(5):831-7. PubMed ID: 9588734
    [Abstract] [Full Text] [Related]

  • 17. Herpes zoster in juvenile-onset systemic lupus erythematosus: incidence, clinical characteristics and risk factors.
    Lee PP, Lee TL, Ho MH, Wong WH, Lau YL.
    Pediatr Infect Dis J; 2006 Aug 18; 25(8):728-32. PubMed ID: 16874173
    [Abstract] [Full Text] [Related]

  • 18. Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort.
    Yang SC, Lai YY, Huang MC, Tsai CS, Wang JL.
    Lupus; 2018 Oct 18; 27(11):1819-1827. PubMed ID: 30103646
    [Abstract] [Full Text] [Related]

  • 19. Herpes zoster in patients with systemic lupus erythematosus.
    Moutsopoulos HM, Gallagher JD, Decker JL, Steinberg AD.
    Arthritis Rheum; 1978 Oct 18; 21(7):798-802. PubMed ID: 697950
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.